Please assess the completion status of the following clinical trial:

Trial Title: Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \> 18 years of age~* Planning for outpatient surgical treatment of SUI with placement of a transobturator suburethral sling under general anesthesia~Exclusion Criteria:~* Pregnant or nursing~* Allergy to bupivacaine~* History of drug/alcohol abuse~* Severe cardiovascular, hepatic, renal disease, or neurological impairment°~* Long-acting opioid within 3 days or any opioid use within 24 hours before surgery~* Contraindication to:~* acetaminophen~* oxycodone~* non-steroidal anti-inflammatory drugs (NSAID)~* Administration of an investigational drug within 30 days before study~* Chronic pain syndromes~* Daily NSAID/opioid use~* Patients having concomitant procedures or not undergoing general anesthesia~* Patients who require a concomitant anterior repair or urethrocele repair will not be excluded as this requires the same dissection in the anterior vaginal wall.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Liposomal bupivacaine (Type: ACTIVE_COMPARATOR): Subjects in this arm will received the drug - liposomal bupivacaine 30 ml.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in this arm will received the placebo - normal saline 30 mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).